Hims & Hers Health (NYSE:HIMS) Insider Sells $691,808.05 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 25,111 shares of the business’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the transaction, the insider owned 313,964 shares of the company’s stock, valued at $8,649,708.20. This represents a 7.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Trading Up 5.7%

Shares of NYSE:HIMS opened at $33.67 on Friday. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market cap of $7.86 billion, a P/E ratio of -53.44 and a beta of 2.40. The stock’s fifty day moving average price is $32.37 and its 200-day moving average price is $26.14.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The business had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. During the same quarter in the previous year, the business posted $0.17 earnings per share. Hims & Hers Health’s quarterly revenue was up 38.2% compared to the same quarter last year. Sell-side analysts expect that Hims & Hers Health, Inc. will post -0.14 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on HIMS shares. Citigroup lowered their price objective on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. TD Cowen increased their price target on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a report on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and an average target price of $32.17.

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Versant Capital Management Inc lifted its position in shares of Hims & Hers Health by 801.2% in the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after acquiring an additional 665 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the period. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Bogart Wealth LLC grew its position in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after purchasing an additional 632 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in Hims & Hers Health during the 1st quarter valued at approximately $30,000. Institutional investors own 63.52% of the company’s stock.

Key Headlines Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Analysts and investors see continued expansion opportunities in branded GLP-1 weight-loss products, testosterone, peptides, international markets and AI-driven patient support. These initiatives could strengthen revenue growth and improve operating efficiency over time. What is driving HIMS stock’s rally
• Positive Sentiment: Barclays maintained an “overweight” rating, indicating a favorable long-term view even after reducing its price target from $39 to $35. The revised target remains above the referenced trading level. Barclays price-target update
• Neutral Sentiment: Recent insider sales by CFO Oluyemi Okupe and other executives were made under pre-arranged Rule 10b5-1 plans. While the transactions may create a modest overhang, the insiders continued to hold sizable positions, reducing the signal that management confidence has materially weakened. HIMS insider sales
• Neutral Sentiment: Analyst views remain divided. Needham raised its price target to $42 and kept a Buy rating, while the broader consensus remains Hold, reflecting strong revenue growth but uncertainty around margins and the GLP-1 strategy.
• Negative Sentiment: Three law firms announced investigations into potential securities-law violations. These announcements are investor outreach notices—not findings of wrongdoing—but they add legal, compliance and reputational risk amid scrutiny of privacy practices, billing and subscription cancellations. Kaplan Fox investigation
• Negative Sentiment: The latest quarterly results showed revenue of $753.2 million, up 38.2% year over year and above expectations, but the company reported a $0.37-per-share loss versus the expected $0.05 loss. Persistent losses and weak profitability could limit further upside unless margins improve.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.